(2023 On-Demand) Anticoagulation Options: DOAC vs Left Atrial Occlusion Device

CME Credit Available:

This activity offers .75 1A AOA 

Note: ACOI reports credits to the AOA after the end of each quarter.

Learning Objectives:

In this session, you'll learn how to:  

• Define the recommendations for use of Novel Oral Anticoagulants (NOACs) for treatment of Atrial Fibrillation and exclusion criteria for their use based upon the 2019 ACC/AHA/HRS Focused Update of Treatment Guidelines to Prevent Thromboembolism in Patients with Atrial Fibrillation.
• Discuss the research literature that led to the Centers for Medicare Services (CMS) to adopt the National Coverage Decision for Left Atrial Appendage Occluder Device Implant and review the specific criteria that must be met for a patient to be considered eligible to receive a Left Atrial Appendage Occluder Device.
• Discuss the up-to-date literature that compares Left Atrial Appendage Occlusion, Direct Oral Anticoagulants and Warfarin usage for patients with Nonvalvular Atrial Fibrillation

Conflict of Interest Disclosures: 

ACOI requires each planner and presenter to identify all conflicts of interest and mitigates risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

Dr. Faulknier, faculty for this activity, has no relevant relationships with ineligible companies to disclose. 

Release & Review Date: 

This activity is valid from May 13, 2023, until May 13, 2026.